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Background: Fasting during Ramadan is a form of intermittent fasting in which a person
abstains from oral intake between the hours of sunrise and sunset. The fasting month
of Ramadan is observed by Muslims worldwide. People with type 1 diabetes (T1DM)
who choose to fast during Ramadan are at a particularly high risk of acute diabetes
complications including hypoglycemia and significant hyperglycemia. We hypothesized
that people with uncomplicated T1DM would be able to fast safely during Ramadan
following structured education and with daily advanced glucose monitoring.
Methods: People with stable and uncomplicated T1DM treated with multiple daily
injections (MDIs) or continuous subcutaneous insulin infusion (CSII) who chose to fast
during Ramadan were recruited for the study. Participants attended Dose Adjustment
for Normal Eating (DAFNE) structured education training, and basal insulin was reduced
in a controlled fashion. Participants were assigned a sensor-augmented insulin pump
or FreeStyle Libre for advanced glucose monitoring. The primary endpoint was the rate
of hypoglycemia during Ramadan compared to before Ramadan. Secondary endpoints
were percentage time spent <4 mmol/L, >10 mmol/L (range, 4–10 mmol/L), episodes
of diabetic ketoacidosis (DKA), and acute kidney injury or hospitalization for any cause.
Results: Rates of hypoglycemia were significantly reduced during Ramadan compared
with rates before Ramadan (0.53± 0. 49 vs. 0.81± 0.69 episodes/day, p= 0.0015). No
episodes of severe hypoglycemia, DKA, acute kidney injury, or hospitalization occurred
during Ramadan period. Percentage time spent >10 mmol/L (46.7 ± 17.7% vs. 42.5 ±
16.4%, p = 0.03) was significantly increased, and percentage time [range, 4–10 mmol/L
(48.8 ± 15.9% vs. 50.9 ± 15.9%, p = 0.13)] and percentage time spent <4 mmol/L
(4.7 ± 5.4.7% vs. 5.7 ± 6.3%, p = 0.09) were reduced, but these differences were
not significant.
Conclusions: People with uncomplicated T1DM could safely participate in intermittent
fasting similar to Ramadan fasting if equipped with structured education and advanced
glucose monitoring systems.
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INTRODUCTION
Intermittent fasting has increased in popularity in recent years
because of accumulating evidence regarding its favorable
metabolic impact on various aspects of human health.
Intermittent fasting can reduce cardiovascular risks and
improve cardiovascular health (1–3), improve insulin sensitivity
and lead to weight reduction (4), mitigate hypertension (5, 6),
and reduce inflammation (7). Fasting during the holy month
of Ramadan is practiced by Muslims worldwide and involves
abstaining from all oral intakes between sunrise and sunset.
Typically, patients with underlying disease or illness are
exempted from fasting unless it is performed in a controlled
environment where risks and complications are minimal or
avoided. Certain individuals with T2DM who have a controlled
diet or are managed using medications that do not increase
the risk of hypoglycemia can fast in a safe manner. However,
fasting is not recommended in individuals with T1DM because
of their particularly high risk of hypoglycemia. Some individuals
with T1DM feel that they are sufficiently healthy to fast during
Ramadan despite the safety concerns of their health care
professionals. These cases require measured and tailored support
in order to minimize potential risks (8, 9). Poorly managed
fasting could cause kidney damage, including acute kidney
injury secondary to dehydration, which is compounded by the
concomitant use of nephrotoxic medications, and hypoglycemia
when endogenous counter-regulatory mechanisms fail to match
the energy expenditure. Although the benefits of planned and
well-supported fasting outweigh the risks in a select group of
individuals with T2DM, the primary challenge that patients
with T1DM face when attempting to fast is the complete
lack of glucose regulation, and thereby, the unacceptable risk
of hypoglycemia and significant hyperglycemia. Because of
the absence of endogenous insulin production, individuals
with T1DM require exogenous insulin to prevent diabetic
ketoacidosis (DKA), even in situations wherein glucose levels
are not elevated (10). Although glycogenolysis, gluconeogenesis,
and negative feedback of insulin secretion are protective against
fasting-induced hypoglycemia in normal physiology, they may
not have the same impact in individuals with T1DM. Individuals
with T1DM have an inherently higher risk of hypoglycemia due
to the hypoglycemic effect of unregulated exogenous insulin
therapy. Other potentially predisposing risks for hypoglycemia
include impaired or loss of glucagon response to hypoglycemia
in long-standing T1DM (11), increased risk of celiac disease (12),
and increased risk of hypoadrenalism due to the predisposition
of a shared autoimmune background (13). A previous study
on fasting in patients with poorly controlled T1DM reported
wide fluctuations in glucose levels with increased hyperglycemia,
more so during the eating period, and significant incidence
of hypoglycemia during the fasting period (14). Kadiri and
colleagues demonstrated that the rate of hypoglycemia was
halved and 2-h postprandial glucose was lower after Iftar (fast-
breaking meal) when using insulin lispro compared with regular
human insulin in individuals with T1DM treated with basal
isophane insulin who fasted during Ramadan (15); albeit risk
of hypoglycemia persisting. An assessment of adolescents with
T1DM who were treated with either basal-bolus or pre-mixed
insulin and who attempted to fast during Ramadan reported that
61.5% of those on basal-bolus and 44% on pre-mixed insulin
broke fasting due to hypoglycemia, whereas 7.6% on basal-bolus
and 55% on pre-mixed insulin broke fasting due to significant
hyperglycemia (16). The current standard therapy approach for
T1DM involves basal-bolus insulin treatment with multiple daily
injections (MDI) using analog insulin preparations; however,
some patients with hypoglycemia or poor glycemic control may
require continuous subcutaneous insulin infusion (CSII) via
an insulin pump (17, 18). An observational study by Benbarka
and colleagues reported a much lower rate of hypoglycemia in
patients with T1DM treated with CSII, although one patient
(2%) was admitted to the hospital with significant hyperglycemia
(19). Khalil and colleagues reported similar observations in
patients with T1DM who fasted Ramadan while using CSII,
with no severe hypoglycemia and less than half of the minor
hypoglycemic episodes occurring during the fasting periods (20).
In another study, Alamoudi and colleagues recruited patients
with T1DM who were treated with either MDI or CSII who
wanted to fast Ramadan. Both groups achieved similar outcomes
with under 10% experiencing mild hypoglycemia and around 1%
experiencing severe hypoglycemia in both groups (21).
Advanced glucose monitoring systems including flash glucose
monitoring (Flash) and continuous glucose monitoring (CGM)
have increased in popularity in recent years because of the high
level of details provided on glucose monitoring, enhanced level
of accuracy, and a growing evidence base for impact and clinical
utility provided by clinical trials (22–24). Flash and CGM systems
measure interstitial fluid glucose which is intrinsically delayed
from blood glucose. The primary difference between Flash and
CGM is that CGM provides real-time glucose readings and
alarms when glucose is low or getting low, while Flash is user-
dependent and provides a glucose reading only when the user
actively scans the sensor. Both systems provide trend arrows
indicating predicted glucose change.
CURRENT GAPS IN THE LITERATURE
Experts from various countries proposed a consensus guideline
for fasting in Ramadan in people with diabetes mellitus (25),
which was followed by two subsequent updates (26, 27). These
guidelines point out the limited and weak evidence from
randomized controlled trials (RCTs) especially in patients with
T1DM and Ramadan fasting. The recommendations in the
guideline were based on opinion and personal experiences rather
than being rigorously tested or evaluated in clinical trials.
The Epidemiology of Diabetes and Ramadan (EPIDIAR)
study group, reported a large observational survey of individuals
with diabetes who fasted during Ramadan. There was increased
rate of acute complications in both T1DM and T2DM
groups (28). The T1DM group had a 4.7-fold increase in
severe hypoglycemia incidence (with or without ketoacidosis).
However, 78% of patients were treated with twice-daily pre-
mixed insulin. The standard of care varied significantly between
participating centers with 10.3% not receiving regular diabetes
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care and only 68% of those in the T1DM group received
Ramadan specific treatment recommendations with 67% were
self-monitoring their blood glucose.
The National Institute for Health and Care Excellence (NICE)
has recommended the implementation of structured educational
programs to enhance individuals’ knowledge regarding diabetes
and improve their management (29). Educational programs train
individuals to safely cope with specific situations, such as exercise
or illness; however, there is a lack of education on fasting and
insulin therapy. One of the most effective educational programs
is the Dose Adjustment for Normal Eating (DAFNE) course,
a 5-day structured educational program for adults with T1DM
to empower them to adjust their insulin dose according to
grams of carbohydrates consumed in their food. Several studies
have reported improved HbA1C and quality of life without
an increased risk of hypoglycemia (30, 31). This UK-based
educational program was adopted and adapted for use in the
Kuwait region. Dasman Diabetes Institute has been endorsed by
DAFNE UK to be the training center for DAFNE in the Middle
East. In addition to the DAFNE standard curriculum, a fasting-
specific educational session on safe fasting during Ramadan
is conducted annually for all DAFNE graduates. The session
seeks to gauge participants’ views and preferences on fasting and
reviews common foods consumed during Ramadan along with
structured therapy recommendations for both MDI and insulin
pump users.
STUDY HYPOTHESIS
In the present study, we hypothesized that structured
education and advanced glucose monitoring could facilitate
safe intermittent fasting during Ramadan without increasing
the risk of hypoglycemia or hyperglycemia in individuals with
uncomplicated T1DM.
METHODS
Design
This non-randomized open-label study included patients with
type 1 diabetes (T1DM) who were treated with CSII or
MDI, who were DAFNE graduates and were either on, or
provided with, CGM (CSII participants) or Flash (MDI and CSII
participants). The primary endpoint was the rate of moderate-
to-severe hypoglycemia or clinically significant hyperglycemia
with or without DKA. Secondary endpoints included the rate of
hypoglycemia, percentage time spent <4 mmol/L, >10 mmol/L,
or in the range of 4–10 mmol/L, episodes of DKA, acute
kidney injury, or hospitalization for any cause during Ramadan
compared to the preceding and following months.
Setting
Participants were recruited, and the study was conducted at
Central DAFNE Kuwait, with approval from the Institutional
Review Board at the Kuwaiti Ministry of Health (2016/435). All
included participants provided informed written consent.
Study Cohort and Inclusion/Exclusion
Criteria
All Kuwaiti residents (Arabs) with T1DM aged ≥18 years
attending Dasman Diabetes Institute for their diabetes care who
chose to fast during Ramadan (May 17, 2018 through June 15,
2018) were assessed for suitability by the diabetes care multi-
disciplinary team (MDT) at Central DAFNE Kuwait. Exclusion
criteria included ≥1 episodes of severe hypoglycemia in the
previous 12 months, poor diabetes control defined as HbA1C
> 75 mmol/mol (9%), established kidney disease defined as
estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73
m2 with or without albuminuria, T1DM diagnosed <1 year
ago, ≥1 episodes of DKA in the previous 12 months, inability
to monitor capillary glucose for a minimum of 4 times a day,
not being DAFNE graduate, inability to attend Ramadan-specific
DAFNE workshop before beginning of Ramadan 2018, and
treatment with pre-mixed insulin preparations. Patients with any
of these conditions were advised against fasting.
Patients treated with CSII were provided with NovoRapid for
the insulin pump (Novo Nordisk, Bagsværd, Denmark), whereas
those treated with MDI were administered insulin glargine U100
(Sanofi, Gentilly, France) and NovoRapid insulin. All patients
underwent advanced glucose monitoring. Those treated with
CSII were either on Medtronic MiniMed 640G with Guardian
Link and Enlite 2 sensor or Medtronic Paradigm Veo insulin
pump with either MiniLink and Enlite-2 sensor (Medtronic,
Northridge, CA, USA) or Abbott FreeStyle Libre Flash system
(Abbott Diabetes Care Inc., Alameda, CA, USA). Participants
treated with MDIs where either existing users of FreeStyle Libre
or they were started on it after dedicated training in preparation
for fasting. All participants received standard capillary glucose
monitoring using the Contour Next glucose meter (Ascensia
Diabetes Care, Basel, Switzerland). Subjects were provided with
ketone testing strips to use with the FreeStyle Libre or Optium
Neo ketone monitoring system (Abbott Diabetes Care Inc.,
Alameda, USA), if they were not on Flash, to use when feeling
unwell or when glucose was >14 mmol/L (250 mg/dL).
Structured Education and Diabetes
Management During Ramadan
DAFNE course and Ramadan-specific DAFNE workshop were
delivered in Arabic, the participants’ mother tongue. Decisions
on fasting during Ramadan and support during the fasting period
were made using a stepped approach. One-on-one consultations
were scheduled within 2 weeks before the start of Ramadan with
each subject who fulfilled the inclusion/exclusion criteria and
planned to fast. Expectations were set and full instructions on safe
fasting were discussed. Participants deciding to proceed agreed
to follow an insulin modification plan during the fasting month.
They were directed to use the highest pre-Ramadan insulin-to-
carbohydrate ratio (ICR) for Iftar and to use the lowest meal ICR
for Suhoor (pre-dawn meal). Those on MDIs were instructed to
reduce their basal insulin by 20% if they were on a once-daily
dose or reduce the evening-morning dose by 20% if they were on
a twice-daily dose. Participants on CSII had a Ramadan-specific
basal profile programmed into their devices with a 20% reduction
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in basal rates from dawn until 2 h before sunset, followed by
a 30% reduction over the next 2 h (the time of breaking the
fast) when the basal rate was increased by 10% for 2 h before
returning to the standard basal rate until dawn. Furthermore,
participants were trained to use a temporary basal tool to manage
hypoglycemia or hyperglycemia when necessary. All patients
treated with CSII were given insulin pens (NovoRapid FlexPen
and Lantus SoloStar pen) to use in case of pump malfunction
or failure. Continuous use of glucose sensors (CGM or Flash)
was emphasized and encouraged. SMBG check was requested
upon waking, at midday, at 3 p.m., before Iftar, before Suhoor,
at midnight, and before going to sleep in addition to other
relevant times including before driving and when feeling unwell
or hypoglycemia is suspected. All included participants were
invited to a 2-day educational workshop conducted by the MDT
before the start of Ramadan. The workshop consisted of a
carbohydrate counting refresher session with emphasis on the
most commonly consumed foods and drinks during Ramadan.
Participants were advised to break their fast when they developed
hypoglycemia (SMBG < 4.0 mmol/L, 72 mg/dL), when their
glucose sensor indicated hypoglycemia (glucose < 4.0 mmol/L,
72 mg/dL) or when hypoglycemia was impending (downward
arrow with expected glucose to reach <4.0 mmol/L, 72 mg/dL
in 15min), when glucose was >14 mmol/L (252 mg/dL) with an
upward arrow, when ketones were >1.5 mmol/L with or without
hyperglycemia, or when the patient felt unwell. All participants
were provided ketone testing strips to use when glucose was
>13 mmol/L (234 mg/dL) or when they felt unwell regardless
of glucose level. All participants were contacted daily via phone
to check on their well-being and to collect information on any
hypoglycemic episodes and the number of days fasted. They were
also provided with a 24-h helpline to contact the study team
when urgent advice is required. Participants were asked to ensure
family members are aware of their participation in the study
and to call for an ambulance if they feel very unwell. They were
also invited to DAFNE clinics during Ramadan whenever their
presence was considered clinically necessary.
Standard demographic data were collected for all participants.
A baseline assessment was performed on all participants within 1
month before Ramadan includingHbA1C, weight, and bodymass
index assessment, current insulin regimen, hypoglycemic history,
and diabetes-related complications. These assessments were
repeated at the end of Ramadan and 1 month after Ramadan.
Statistical Analysis
All devices were downloaded before Ramadan, at the end of
Ramadan, and 1 month after Ramadan. Data were separated
for the periods before, during, and after Ramadan, and the
Ramadan period was separated into periods of fasting and eating.
Participants not including a minimum of 1 complete day of
glucose data in their profiles were excluded. Average glucose was
calculated for all glucose values in each captured period divided
by the number of days of valid data collected. Time spent >10
mmol/L (180 mg/dL), time spent in the range of 4–10 mmol/L
(72–180 mg/dL), time spent <4 mmol/L (72 mg/dL), and time
spent <3.0 mmol/L (54 mg/dL) were calculated as percentages
of overall captured glucose data for the time periods outlined. All
continuous episodes of hypoglycemia were assessed when glucose
values were <4 mmol/L for a minimum of 3 consecutive logged
readings. The rate of hypoglycemia was calculated as the total
number of hypoglycemic episodes divided by the total number of
days in each period. Glucose variability (GV) was evaluated with
the coefficient of variation (CV) and the slope index (SI). The
CV was calculated as the standard deviation divided by average
glucose for the calculated period then multiplied by 100. SI was
calculated according to the following formula:
SI =
∑tn
t0
∣∣∣ dGdT
∣∣∣
total days
Where SI is slope index, t is time point, dG is change between
consecutive glucose values, and dT is change in time interval
for each glucose value. SI measures the total intensity of glucose
changes during the examined period.
Percentage of area under the curve for time spent>10mmol/L
(180 mg/dL) was calculated according to the following formula:
%AUCt > 10 =
∑tn
t0
(
g1+g2
2
)
∗ (t2− t1)
total days
Where AUCt > 10 is area under the curve for time spent >10.0
mmol/L (180 mg/d/L), t is time point, and g is glucose values
>10 mmol/L.
Similarly, area above the curve for time spent <4.0 mmol/L
(72 mg/dL) was calculated according to the following formula:
%AACt < 4 =
∑tn
t0
(
4
t2−t1
)
−
((
g1+g2
2
)
∗ (t2− t1)
)
total days
Where AACt < 4 is the area above the curve for time spent
<4.0 mmol/L, t is time point, and g is glucose when glucose
<4 mmol/L.
The paired Student t-test was used to measure significant
differences between means of parameters in different periods and
groups. Differences were considered significant when p values
were <0.05.
RESULTS
A total, 43 participants were enrolled in the study, their
characteristics are summarized (Table 1). All subjects educational
level was of high school and above. Pre-existing diabetes-related
complications were present in 5 (12%), all of which were diabetic
retinopathy except 1 case related to cardiovascular disease (CSII
group). All participants were graduates of the DAFNE structured
education program. In the CSII group, 12 participants were
managed with Medtronic MiniMed 640G and 9 were managed
with Medtronic Paradigm Veo insulin pump (CSII). All CSII
subjects had augmentation with an Enlite-2 sensor through
the Guardian Link and MiniLink CGM system except 3 with
Paradigm Veo who used Abbott FreeStyle Libre (FSL) Flash.
Participants were on CSII therapy for 4.2 ± 2.4 (mean ± SD)
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TABLE 1 | Summary of participants’ characteristics.
All CSII MDI P value
Number 43 21 22
Gender F (%) 21 (49) 10 (48) 11 (50)
Age 31.7 ± 82 34.6 ± 8.6 30.3 ± 7.7 NS
BMI 23.6 ± 10 25.9 ± 7.5 21.5 ± 11.7 NS
Duration of Diabetes 16 ± 6.5 15 ± 6 16.7 ± 8.5 NS
HbA1c % 7.7 ± 1.1 7.2 ± 0.8 8.2 ± 1.2 0.002
Diabetes related complications 5 2 3
Enlite-2 CGM (%) 18 (42) 18 (86%) 0 (0%)
FreeStyle Libre (%) 25 (58) 3 (14) 22 (100%)
Data presented as absolute numbers or means ± SD as relevant. Comparison was made
between the CSII group and MDI group. P value < 0.05 was considered statistically
significant. NS, not significant.
TABLE 2 | Comparison between subjects according to the number of days fasted
in Ramadan.
Days fasted out of 29 days duration of Ramadan
20–29 days 10–19 days <10 days
Total number 23 (54%) 16 (37%) 4 (9%)
Number of females 9 (39%) 10 (63%) (NS) 2 (50%)
Duration of diabetes (years) 16 ± 7.5 16 ± 8.3 (NS) 11.5 ± 3.5
HbA1C (%) 7.4 ± 1.01 7.8 ± 1.1 (NS) 8.6 ± 0.9
BMI kg/M2 23 ± 1.3 24 ± 11.2 (NS) 23.3 ± 2.9
CSII/MDI % 78/22% 19/81%* 0/100%
NS, not significant; *indicates statistically significant difference (p < 0.05) between CSII
and MDI groups. Data presented as mean ± SD.
years prior to the study. TheMDI group included 22 participants,
all of whom had concomitant use of Flash. The average duration
of Flash use was 5.4 ± 4.6 (mean ± SD) months before the start
of the study. Participants fasted for a median of 23 days (range,
4–29). More than half of participants (54%) fasted between 20
and 29 days out of 29 fasting days in Ramadan 2018, while
37% fasted between 10 and 19 days and 9% fasted <10 days.
There were significantly more subjects treated with CSII (78%)
in those who fasted 20–29 days while other parameters including
duration of diabetes, number of females, HbA1C, and BMI were
comparable with those who fasted 10–19 days (Table 2). Reasons
for not fasting included menstrual period in female participants,
work related-causes, not feeling well (not related to diabetes), and
glucose disturbance during the eating period.
Diabetes Control and Hypoglycemia
Total daily dose (TDD) of insulin was 8.3% lower during
Ramadan than before Ramadan and was accompanied by a small
but significant rise in glucose by 0.5 mmol/L (9 mg/dL) during
Ramadan compared with before Ramadan (Table 3). There was
a non-significant drop in HBA1c after Ramadan compared to
before Ramadan [61 ± 8.7 vs. 58 ± 8.5 mmol/mol (7.7 ± 1.1%
vs. 7.5 ± 1.1%)] (p = 0.2). CGM and Flash profiles showed a
significant 4% increase in percentage time spent >10 mmol/L
(180 mg/dL) with no significant difference for percentage time
spent in the range of 4–10 mmol/L (72–180 mg/dL) or time
spent <4.0 mmol/L (72 mg/dL) (Figure 1). No DKA or hospital
admission occurred during Ramadan.
None of the participants experienced severe hypoglycemia
during the fasting period. The number of hypoglycemic episodes
detected on glucose monitoring was significantly reduced during
Ramadan compared with rates before Ramadan (0.53 ± 0.48 vs.
0.81± 0.69 hypoglycemic episodes/day, mean± SD, p= 0.0014)
(Figure 2). Moreover, reduction in time spent <3.0 mmol/L (54
mg/dL) and time spent <4.0 mmol/L (72 mg/dL) as well as the
area above the curve for time spent <4.0 mmol/L (72 mg/dL)
were also observed but was only significant in the CSII + CGM
group (Table 3).
Glucose Variability
In the overall cohort, no difference was observed in glucose
CV during Ramadan compared with before or after Ramadan;
however, it was significantly lower in the CSII + CGM
group during Ramadan compared to before Ramadan (Table 3).
Interestingly, the reduction in glucose CV in the CSII + CGM
group was maintained after Ramadan (Figure 3A). Similarly, SI
was smaller during Ramadan than before Ramadan, an effect that
was maintained after Ramadan in the whole cohort (Figure 3B),
denoting a reduction in GV.
Fasting vs. Non-fasting Periods During
Ramadan
Average glucose was significantly lower during the fasting period
compared with the eating period, although the difference was
small [10.0 ± 1.9 vs. 10.8 ± 2.9 mmol/L (180 ± 34.2 vs.
194.4 ± 52.2 mg/dL), respectively, p = 0.01]. The overall
rate of hypoglycemia was lower during Ramadan compared
to before or after Ramadan, however, a small but significant
increase in the rate of hypoglycemia occurred during the fasting
period compared to the eating period (0.31 ± 0.28 vs. 0.18 ±
0.19 hypoglycemic episode/patient/day, respectively, p = 0.003).
During the fasting period, participants spent significantly more
time in the range of 4–10 mmol/L [72–180 mg/dL (percentage
time spent was 50.7 ± 16.3 vs. 45.3 ± 8.5%, respectively, P =
0.017)] and less time spent >10 mmol/L (180 mg/dL) compared
to the eating period (percentage time spent was 44.6 ± 17.9 vs.
50.5± 21.4%, p= 0.019), with similar time spent<4 mmol/L (72
mg/dL) in both periods (percentage time spent 5.0 ± 5.2 vs. 4.5
± 4.1%, p= 0.66) (Figure 4).
DISCUSSION
The present study met its primary and secondary endpoints
and showed that it was possible for a group of individuals with
uncomplicated T1DM who received structured education and
used advanced glucose monitoring to safely observe intermittent
fasting during the month of Ramadan without an increase
in hypoglycemia and no incidence of severe hypoglycemia or
significant hyperglycemia while maintaining reduced GV during
the fasting month. While the EPIDIR study, demonstrated
increased risk of hypoglycemia, including severe hypoglycemia,
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TABLE 3 | Summary of fasted days, insulin, and glucose data analysis from CGM or Flash for the periods before, during, and after Ramadan.
Parameters Patients groups
Total (no. 43) CSII + CGM (no. 18) MDI + Flash (no. 22)
Before Ramadan During Ramadan After Ramadan Before Ramadan During Ramadan After Ramadan Before Ramadan During Ramadan After Ramadan
Days fasted – 20 ± 8 – – 25 ± 5 – – 15 ± 8‡ –
Days included in glucose analysis 15 ± 9 19 ± 8 20 ± 11 15 ± 8 21 ± 6 16 ± 9 17 ± 8 18 ± 9 22 ± 11
TDD 51.2 ± 25.7 47.0 ± 23.7* 48.8 ± 23.7* 48.8 ± 20.7 45.0 ± 20.7 47.8 ± 20.1 54.6 ± 31.0 49.9 ± 27.4 51.0 ± 28.1
TBI 22.0 ± 8.5 20.2 ± 8.4 21.0 ± 8.4 21.1 ± 8.2 18.8 ± 7.9 20.7 ± 8.5 23.2 ± 9.1 21.7 ± 9.1 21.7 ± 8.6
Average glucose 9.8 ± 1.9 10.3 ± 2.0*§ 9.7 ± 1.6 9.0 ± 0.7 9.6 ± 1.1*§ 9.1 ± 0.8 10.4 ± 2.3 10.7 ± 2.4§ 10.0 ± 1.7
HbA1c 7.7 ± 1.1 – 7.5 ± 1.1 7.1 ± 0.8 – 7.1 ± 0.8 8.2 ± 1.2 – 7.8 ± 1.2
% time spent <3 mmol/L 2.19 ± 4.4 1.5 ± 2.3 2.0 ± 2.7 1.1 ± 1.3 0.6 ± 0.8* 0.6 ± 0.9 3.6 ± 6.3 2.4 ± 3.0‡ 3.1 ± 3.2‡
% time spent <4 mmol/L 5.7 ± 6.3 4.7 ± 4.7 8.4 ± 12.3 4.8 ± 3.4 2.8 ± 3.0*§ 3.0 ± 3.0* 7.2 ± 8.7 6.5 ± 5.4 12.6 ± 15.5
% time spent 4–10 mmol/L 50.9 ± 16.0 48.8 ± 15.9 49.7 ± 18.7 60.1 ± 8.1 56.1 ± 10.6§ 61.3 ± 9.3 45.6 ± 14.7‡ 43.1 ± 15.6‡ 42.8 ± 19.6‡
% time spent >10 mmol/L 42.5 ± 16.4 46.7 ± 17.7*§ 42.0 ± 15.4 35.1 ± 7.8 41.1 ± 12.2*§ 35.7 ± 9.5 47 ± 18.6 50.8 ± 18.9 44.6 ± 15.8
No. Hypo per day 0.81 ± 0.69 0.53 ± 0.48* 0.61 ± 0.48 1.21 ± 0.65 0.60 ± 0.49*§ 0.70 ± 0.54* 0.49 ± 0.56‡ 0.46 ± 0.49 0.58 ± 0.47
AUC for time spent >10 mmol/L 132.2 ± 65.2 146.6 ± 73.1§ 126.6 ± 56.5* 106.12 ± 24.3 124.5 ± 43.3*§ 104.3 ± 30.1 150.0 ± 76.3‡ 161.3 ± 81.8 135.3 ± 55.1*‡
AAC for time spent <4.0 mmol/L 1.10 ± 1.83 0.74 ± 0.94 0.86 ± 1.02 0.74 ± 0.65 0.43 ± 0.51* 0.43 ± 0.50 1.52 ± 2.67 1.06 ± 1.16 1.20 ± 1.22
CV 39.7 ± 6.2 39.8 ± 8.2 38.6 ± 7.1 38.5 ± 4.5 35.6 ± 5.2* 34.6 ± 5.2* 42.3 ± 6.5 42.1 ± 9.6‡ 41.3 ± 6.7‡
Slope index 8.29 ± 5.19 7.22 ± 4.47* 6.66 ± 4.25* 13.55 ± 1.85 11.89 ± 1.86* 12.04 ± 0.94* 3.68 ± 0.65‡ 3.40 ± 0.91‡ 3.44 ± 0.61‡
Data presented for all cohort (total) and for sub-groups CSII+ CGM and MDI+ Flash. TDD, total daily dose; TBI, total basal insulin; AUC, area under the curve; AAC, area above the curve; CV, coefficient of variation. *Indicates statistically
significant differences (p < 0.05) between Ramadan and before the Ramadan periods within same group. § Indicates statistically significant differences between Ramadan and after the Ramadan periods within same group. ‡ Indicates
statistically significant differences between CSII + CGM group and MDI + Flash groups for the corresponding period. Data presented as mean ± SD.
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FIGURE 1 | Percentage time spent >10 mmol/L, between 4 and 10 mmol/L,
and <4 mmol/L for the periods before, during and after Ramadan in the whole
cohort. Data represents mean ± SEM, *represent statistically significant
differences (p < 0.05).
FIGURE 2 | Rate of hypoglycaemia before, during, and after Ramadan. Data
represents mean ± SEM, *represent statistically significant differences (p <
0.05).
and hyperglycemia/DKA in those with diabetes mellitus who
fasted Ramadan (28), other studies reported better outcomes
in those with T1DM who fasted Ramadan following Ramadan
specific education (32), used analog insulin compared to human
insulin (15, 33), or used insulin pumps (19, 20, 34). Alamoudi
recently reported similar outcomes in those on CSII compared to
those onMDI using analog insulin preparations during Ramadan
fasting, though severe hypoglycaemia was reported in 1.3% (21).
Several factors contributed to the favorable outcome of
our study. First, participants with uncomplicated T1DM were
carefully selected for inclusion in the study, as metabolic stress
and the relative state of dehydration anticipated during the
fasting period could aggravate pre-existing complications. This
is particularly important in those with diabetic nephropathy with
reduced GFR because of the increased risk of hypoglycemia in the
present cohort (35) as well as the risk of pre-renal acute kidney
injury secondary to dehydration. Moreover, previous severe
hypoglycemia is the strongest predictor of recurrence (36), and
those with poor diabetes control may not engage safely in glucose
monitoring and diabetes management during the fasting period,
FIGURE 3 | Glucose variability profiles measured before, during, and after
Ramadan, including Coefficient of variation (CV) for CSII + CGM group (A) and
Slope Index (SI) for the whole cohort (B). Data represents mean ± SEM,
*represent statistically significant differences (p < 0.05).
FIGURE 4 | Percentage time spent >10.0 mmol/L, between 4 and 10
mmol/L, and <4 mmol/L during fasting (inner circle) and eating (outer circle)
periods. Data represents means. *represent statistically significant differences
(p < 0.05).
which increases their risk of deterioration. Second, providing all
participants with DAFNE structured education and emphasizing
food options commonly consumed during Ramadan empowered
them to manage their insulin in light of the dietary changes
experienced during Ramadan. Third, providing all participants
with advanced glucose monitoring sensors enabled them to
gain deeper insight into their glucose changes, and therefore,
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mitigate hypoglycemia and hyperglycemia the majority of the
time. Finally, proactively modifying insulin regimens led to
effective therapy with minimal hypoglycemia.
The findings in the present study are relevant to people
with T1DM who choose to observe fasting during Ramadan
as well as to other individuals with T1DM who intend to fast
for other reasons. The study demonstrated in our cohort of
people with uncomplicated T1DM who underwent structured
diabetes education and used advanced glucose monitoring
that they can fast safely whether treated with MDI or CSII.
Although the number of participants was small and the study
was not a randomized trial, the safety outcomes were novel
and quite encouraging in this cohort. Further validation in
larger randomized controlled trials is required. In the meantime,
the protocol adopted in this study could serve as a safe
guiding blueprint for individuals with T1DM who intend to
observe fasting.
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